Please login to the form below

Not currently logged in
Email:
Password:

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from

  • Ipsen’s liver cancer treatment clears phase III trial Ipsen’s liver cancer treatment clears phase III trial

    Ipsen’ s liver cancer treatment clears phase III trial. Cabometyx on track for new liver cancer indication. ... Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first

  • NICE gives green light to Ipsen's Cabometyx NICE gives green light to Ipsen's Cabometyx

    NICE gives green light to Ipsen's Cabometyx. Backs the medicine’s use for patients with advanced kidney cancer. ... Ipsen has persuaded NICE to back its advanced renal cell cancer treatment Cabometyx (cabozantinib) after offering new evidence and a

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    For Ipsen, the deal continues its drive to expand its oncology franchise, currently headed by hormonal therapy Somatuline for neuroendocrine tumours and Cabometyx (cabozantinib) for advanced renal cell carcinoma.

  • Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

    Cabometyx was approved by European regulators just last month as a treatment for advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. ... therapy. French biotech Ipsen signed and

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... As the ESMO meeting began, Ipsen received the news that

  • Charting a course for expansion Charting a course for expansion

    The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics